DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in MYCN-Amplified Neuroblastoma IMR32 Cells

Author:

Ando Kiyohiro1ORCID,Suenaga Yusuke2ORCID,Kamijo Takehiko1ORCID

Affiliation:

1. Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama 362-0806, Japan

2. Chiba Cancer Center Research Institute, Chiba 260-8717, Japan

Abstract

Identifying the vulnerability of altered DNA repair machinery that displays synthetic lethality with MYCN amplification is a therapeutic rationale in unfavourable neuroblastoma. However, none of the inhibitors for DNA repair proteins are established as standard therapy in neuroblastoma. Here, we investigated whether DNA-PK inhibitor (DNA-PKi) could inhibit the proliferation of spheroids derived from neuroblastomas of MYCN transgenic mice and MYCN-amplified neuroblastoma cell lines. DNA-PKi exhibited an inhibitory effect on the proliferation of MYCN-driven neuroblastoma spheroids, whereas variable sensitivity was observed in those cell lines. Among them, the accelerated proliferation of IMR32 cells was dependent on DNA ligase 4 (LIG4), which comprises the canonical non-homologous end-joining pathway of DNA repair. Notably, LIG4 was identified as one of the worst prognostic factors in patients with MYCN-amplified neuroblastomas. It may play complementary roles in DNA-PK deficiency, suggesting the therapeutic potential of LIG4 inhibition in combination with DNA-PKi for MYCN-amplified neuroblastomas to overcome resistance to multimodal therapy.

Funder

JSPS KAKENHI

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Reference34 articles.

1. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report;Cohn;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2009

2. Overall genomic pattern is a predictor of outcome in neuroblastoma;Schleiermacher;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2009

3. The origin of chromosome imbalances in neuroblastoma;Stallings;Cancer Genet. Cytogenet.,2007

4. PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers;Pilie;Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.,2019

5. Nonhomologous DNA end-joining for repair of DNA double-strand breaks;Pannunzio;J. Biol. Chem.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3